InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,477.90
(
0.16%
)
US TECH 100
19,131.60
(
-0.23%
)
Dow Jones
39,127.80
(
0.04%
)
Brent Oil
84.36
(
-0.14%
)
Bitcoin
60,644.32
(
-0.28%
)
Post# of 252389
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119931
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 216870

Friday, 02/02/2018 8:24:07 AM

Friday, February 02, 2018 8:24:07 AM

Post# of 252389
Re: ABBV/ENTA US HCV scripts/week ending 1/26/18 (IMS)

ABBV/ENTA’s new-patient share (NRx) reached 35.6%, the highest-ever level reported by IMS. (Almost all of ABBV/ENTA’s US patient share is now coming from Mavyret.) ABBV/ENTA’s total-patient share (TRx) reached 29.3%.

The actual Mavyret figures reported by IMS for the week ending 1/26/18 are:

NRx 951 (+21% vs prior week)
TRx 1607 (+17% vs prior week)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up